Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961384 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05961384 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 8 participants.
The verdict
NCT05961384, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive \[14C\] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of \[14C\] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.
Interventions
- DRUG baxdrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05961384
The ClinicalTrials.gov registry entry for NCT05961384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which baxdrostat is the first listed.
NCT05961384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05961384 about?
NCT05961384 is a clinical study titled "Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat". This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive \[14C\] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximatel...
What is the current status of trial NCT05961384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-11-18. Estimated completion is 2022-01-15.
What interventions are being tested in trial NCT05961384?
The interventions under investigation include: baxdrostat (DRUG).
Who is sponsoring clinical trial NCT05961384?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.